CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

Citizens has reaffirmed its Market Outperform rating and $80.00 price target on CRISPR Therapeutics shares (NASDAQ:CRSP). The stock's current price stands at $54.23, with analyst targets spanning from $44 to $291, though some data suggest the stock may be overvalued. CRISPR Therapeutics has successfully commercialized a first gene-editing based cell therapy, showcasing its technology's potential.

The company is steadily building a pipeline of late-stage assets, especially in in-vivo therapies for large cardiovascular and metabolic indications. Key early readouts are anticipated in the second half of 2026 for CTX310 (ANGPTL3), CTX611 (TKA), and Zugo-cel (I&I). Analysts are optimistic about CRISPR Therapeutics in 2026, as much of the pipeline opportunity remains undervalued.

The firm projects the potential for late-stage development in up to seven opportunities in 2027. At the European Society of Cardiology, CRISPR Therapeutics unveiled updated data from 15 Phase 1a patients, revealing substantial reductions in lipid levels, such as a 78.6% decrease in ANGPTL3 and a 52.5% reduction in LDL-C after one year.

Subsequently, H.C. Wainwright also maintained its Buy rating with an $80 price target for CRISPR Therapeutics, underscoring the promising data on the CTX310 gene editor. Furthermore, the FDA broadened the label for CRISPR Therapeutics’ gene therapy CASGEVY to encompass patients as young as two years old with specific conditions, a move that H.C.

Wainwright recognized and reiterated its Buy rating. These recent advancements and analyst confidence underscore CRISPR Therapeutics' strong pipeline and market potential.